PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34666245-0	2021	Trelagliptin ameliorates IL-1beta-impaired chondrocyte function via the AMPK/SOX-9 pathway.	trelagliptin	0-12	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	72-76	
34666245-10	2021	Mechanistically, we demonstrate that AMPK is required for the amelioration of Trelagliptin on SOX-9- reduction by IL-1beta.	trelagliptin	78-90	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	37-41	
34435315-8	2021	Lastly, the AMPK pathway was observed to be significantly activated in OGD/R-challenged HAVECs by Trelagliptin treatment.	trelagliptin	98-110	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	12-16	
34435315-9	2021	After co-administration of the inhibitor of the AMPK pathway, the effects of Trelagliptin on mitochondrial function and metabolic alterations were significantly abolished.	trelagliptin	77-89	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	48-52	
34435315-10	2021	Taken together, our data indicate that Trelagliptin ameliorated OGD/R-induced mitochondrial disturbance and metabolic changes by activating the AMPK pathway.	trelagliptin	39-51	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	144-148